Seer (SEER)
(Delayed Data from NSDQ)
$1.78 USD
+0.01 (0.56%)
Updated Aug 6, 2024 03:59 PM ET
After-Market: $1.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SEER 1.78 +0.01(0.56%)
Will SEER be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SEER based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SEER
Seer, Inc. (SEER) Reports Q1 Loss, Misses Revenue Estimates
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
SEER: What are Zacks experts saying now?
Zacks Private Portfolio Services
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom Fisher
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
Other News for SEER
Seer to Report Second Quarter 2024 Financial Results on August 8, 2024
Seer Proteograph? Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
Seer announces publications highlighting studies on Proteograph Product Suite
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ?s Early Cancer Detection Study
Lab Instrument Industry Update - New Commercial Entrants